Related Experiment Videos
Lithium neurotoxicity at therapeutic level--a case report
Journal of the Indian Medical Association
|January 19, 2000
Summary
This case study highlights unusual neurotoxicity from lithium, even at low serum levels (0.5 mEq/L). The patient recovered after discontinuing lithium and starting carbamazepine.
Area of Science:
- Neuroscience
- Pharmacology
- Psychiatry
Background:
- Lithium is a common mood stabilizer for bipolar disorder.
- Therapeutic serum lithium levels are typically 0.6-1.2 mEq/L.
- Lithium toxicity can occur at higher levels, presenting with various neurological symptoms.
Observation:
- A 30-year-old male presented with symptoms suggestive of lithium toxicity.
- Serum lithium levels were measured at 0.5 mEq/L, a level usually considered subtherapeutic.
- Despite the low level, the patient's admission was attributed to neurotoxicity.
Findings:
- Neurotoxicity occurred at an unusually low serum lithium concentration of 0.5 mEq/L.
- Discontinuation of lithium and initiation of carbamazepine led to a favorable clinical response.
- This suggests individual variability in lithium sensitivity and toxicity thresholds.
Implications:
- Clinicians should consider neurotoxicity in patients on lithium, even with seemingly low serum levels.
- Individual patient factors may influence susceptibility to lithium-induced neurotoxicity.
- Carbamazepine can be an effective alternative mood stabilizer in cases of lithium intolerance or toxicity.